Congress-AHA
ACC-2026-mobile

Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2025

Congress Details

calander7-10 November, 2025 | USA

locationNew Orleans, Louisiana

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

Razvi_AHA-2025_H-B-Cardiac-MRI-Poster-FINAL-Nov-7
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial
Manafi_AHA25_H-B-RVFWS-poster_05Nov25_FINAL
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Right Ventricular Free Wall Strain and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy and Effect of Vutrisiran: The HELIOS-B Study
Jering_AHA-LAS-HELIOS-B-20251104_FINAL_updated
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Left Atrial Strain and Clinical Outcomes in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the HELIOS-B Trial on Vutrisiran Efficacy
Sheikh_AHA-2025-H-B-Renal-Pos_D6.0_05Nov_FINAL
icon Presentation Type
Poster
location icon Location
New Orleans, Louisiana
icon Title
Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B

Associated Materials

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00166

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00167
hfsa-congress-usa-mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

26-29 September 2025 USA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00106
eu-attr-italy-mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

25-26 September 2025 ITALY

View Details
Preparation Date
March 2026
Job Code
MB-UK-00113
European Society of Cardiology (ESC) 2025 Congress, Spain

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

29 August - 1 September 2025 SPAIN

View Details
Preparation Date
March 2026
Job Code
MB-UK-00118

Transthyretin Amyloidosis (ATTR)

Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry

June 2025

Preparation Date
March 2026
Job Code
MB-UK-00168
Preparation Date
August 2026
Job Code
MB-UK-00229